Market Analysis

Adjunctive cancer therapies market expected to top $24.5 billion by 2010

Published in Cancer Weekly, May 15th, 2006

With more than 10 million new cases of cancer diagnosed throughout the world every year, revenues from adjunctive therapies used to relieve the side effects of both primary cancer treatments and the disease itself are growing at an annual rate of 7.4% and are expected to reach $24.5 billion by 2010.

According to "The Global Market for Adjunctive Therapies in Cancer," a new study from Kalorama Information, 2005 revenues for therapies addressing nausea, anemia, pain, and infections, among others, exceeded $17 billion. Indeed, from 2003 to 2005, the market grew by nearly 15%, primarily due to strong sales of biological response modifiers, and nausea, emesis, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry